Cargando…

Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014

OBJECTIVES: To report 10-year outcomes of virological and immunological treatment failure rates and risk factors. DESIGN: Prospective cohort study. SETTING: Shenzhen, China. PARTICIPANTS: 2172 HIV-positive adults in the national treatment database of Shenzhen from December 2003 to January 2014. INTE...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Peng, Tan, Jingguang, Ma, Wenzhe, Zheng, Hui, Lu, Yan, Wang, Ning, Peng, Zhihang, Yu, Rongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442238/
https://www.ncbi.nlm.nih.gov/pubmed/26002691
http://dx.doi.org/10.1136/bmjopen-2014-007508
Descripción
Sumario:OBJECTIVES: To report 10-year outcomes of virological and immunological treatment failure rates and risk factors. DESIGN: Prospective cohort study. SETTING: Shenzhen, China. PARTICIPANTS: 2172 HIV-positive adults in the national treatment database of Shenzhen from December 2003 to January 2014. INTERVENTION: Antiretroviral therapy according to the Chinese national treatment guidelines. OUTCOME MEASURES: Virological and immunological treatment failure rates. RESULTS: Of the 3099 patients surveyed, 2172 (70.1%) were included in the study. The median age was 33 years; 78.2% were male and 51.8% were infected through heterosexual contact. The median follow-up time was 31 months (IQR, 26–38). A total of 81 (3.7%) patients died, whereas 292 (13.4%) and 400 (18.4%) patients experienced virological and immunological failures, respectively. Adjusted Cox regression analysis indicated that baseline viral load (HR=2.19, 95% CI 1.52 to 4.48 for patients with a baseline viral load greater than or equal to 1 000 000 copies/mL compared to those with less than 10 000 copies/mL) and WHO stage (HR=4.16, 95% CI 2.01 to 10.57 for patients in WHO stage IV compared with those in stage I) were significantly associated with virological failure. The strongest risk factors for immunological treatment failure were a low CD4 cell count (HR=0.46, 95% CI 0.32 to 0.66 for patients with CD4 cell counts of 50–99 cells/mm(3) compared to those with less than 50 cells/mm(3)) and higher baseline WHO stage at treatment initiation (HR=2.15, 95% CI 1.38 to 3.34 for patients in WHO stage IV compared to those in stage I). CONCLUSIONS: Sustained virological and immunological outcomes show that patients have responded positively to long-term antiretroviral treatment with low mortality. This 10-year data study provides important information for clinicians and policymakers in the region as they begin to evaluate and plan for the future needs of their own rapidly expanding programmes.